| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10616-007-9103-2 |
| P8608 | Fatcat ID | release_eruxqysxzbf5rkjtvvxpyrpxeu |
| P932 | PMC publication ID | 2104554 |
| P698 | PubMed publication ID | 19003000 |
| P5875 | ResearchGate publication ID | 23467447 |
| P2093 | author name string | Yutaka Kanda | |
| Kenya Shitara | |||
| Mitsuo Satoh | |||
| Shigeru Iida | |||
| Naoko Yamane-Ohnuki | |||
| Rinpei Niwa | |||
| Ryosuke Nakano | |||
| Akira Okazaki | |||
| Katsuhiro Mori | |||
| Reiko Kuni-Kamochi | |||
| Toyohide Shinkawa | |||
| Harue Imai-Nishiya | |||
| Akihito Natsume | |||
| P2860 | cites work | The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. | Q54791103 |
| Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma | Q58415142 | ||
| Monoclonal antibody successes in the clinic | Q61163248 | ||
| Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2 | Q62604209 | ||
| Systematic fractionation of oligosaccharides of human immunoglobulin G by serial affinity chromatography on immobilized lectin columns | Q69437692 | ||
| Structural and numerical variations of the carbohydrate moiety of immunoglobulin G | Q71620208 | ||
| Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies | Q72228246 | ||
| Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies | Q73551191 | ||
| Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene | Q77535970 | ||
| Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma | Q77565327 | ||
| Glycobiology | Q22255657 | ||
| Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcgamma RIII and antibody-dependent cellular toxicity | Q30835165 | ||
| CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations | Q33193071 | ||
| Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis | Q33208374 | ||
| Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer | Q33598660 | ||
| Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). | Q33730975 | ||
| Mechanism of action of anti-HER2 monoclonal antibodies | Q34346097 | ||
| Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity | Q34346238 | ||
| Purification and cDNA cloning of porcine brain GDP-L-Fuc:N-acetyl-beta-D-glucosaminide alpha1-->6fucosyltransferase. | Q34406765 | ||
| Engineered antibody Fc variants with enhanced effector function | Q34424958 | ||
| Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies | Q34574834 | ||
| The ErbB receptor family: a therapeutic target for cancer | Q34583857 | ||
| Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer | Q35206358 | ||
| Clinical Experience with Trastuzumab (Herceptin) | Q35583405 | ||
| Rituximab (Rituxan/MabThera): the first decade (1993-2003). | Q35611848 | ||
| History of antibody therapy for non-Hodgkin's lymphoma | Q35622590 | ||
| Glycosylation of recombinant antibody therapeutics | Q36132495 | ||
| Fucose removal from complex-type oligosaccharide enhances the antibody-dependent cellular cytotoxicity of single-gene-encoded antibody comprising a single-chain antibody linked the antibody constant region | Q38319734 | ||
| IgG subclass-independent improvement of antibody-dependent cellular cytotoxicity by fucose removal from Asn297-linked oligosaccharides | Q38320052 | ||
| Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density | Q38328896 | ||
| Enhancement of the antibody-dependent cellular cytotoxicity of low-fucose IgG1 Is independent of FcgammaRIIIa functional polymorphism | Q38336117 | ||
| Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcgammaRIIIa | Q38343329 | ||
| Comparison of cell lines for stable production of fucose-negative antibodies with enhanced ADCC. | Q40293476 | ||
| High concentrations of therapeutic IgG1 antibodies are needed to compensate for inhibition of antibody-dependent cellular cytotoxicity by excess endogenous immunoglobulin G. | Q40384899 | ||
| Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma | Q40562102 | ||
| The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity | Q40690773 | ||
| Comparability testing of a humanized monoclonal antibody (Synagis) to support cell line stability, process validation, and scale-up for manufacturing | Q40903347 | ||
| Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma | Q44802891 | ||
| High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R. | Q46117208 | ||
| Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. | Q47254808 | ||
| Rituximab-mediated depletion of cynomolgus monkey B cells in vitro in different matrices: possible inhibitory effect of IgG. | Q47275450 | ||
| Upping the ante on antibodies. | Q51358173 | ||
| Engineering Chinese hamster ovary cells to maximize effector function of produced antibodies using FUT8 siRNA. | Q51591345 | ||
| Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. | Q51807927 | ||
| P433 | issue | 2-3 | |
| P921 | main subject | antibody | Q79460 |
| P304 | page(s) | 109-114 | |
| P577 | publication date | 2007-10-31 | |
| P1433 | published in | Cytotechnology | Q15752151 |
| P1476 | title | Non-fucosylated therapeutic antibodies: the next generation of therapeutic antibodies | |
| P478 | volume | 55 |
| Q46242617 | A framework for real-time glycosylation monitoring (RT-GM) in mammalian cell culture |
| Q38849069 | A global RNA-seq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation |
| Q41639511 | A simultaneous assessment metric for MAb quantity and glycan quality. |
| Q29347272 | A testis-specific regulator of complex and hybrid N-glycan synthesis |
| Q42153431 | Advantages of AlaGln as an additive to cell culture medium: use with anti-CD20 chimeric antibody-producing POTELLIGENT™ CHO cell lines |
| Q38301805 | Algal lectin binding to core (α1-6) fucosylated N-glycans: structural basis for specificity and production of recombinant protein |
| Q38688747 | Antibodies as stratagems against cancer |
| Q46866013 | Application of human FcRn transgenic mice as a pharmacokinetic screening tool of monoclonal antibody. |
| Q38936714 | Biological roles of glycans |
| Q55333943 | Cell Line Techniques and Gene Editing Tools for Antibody Production: A Review. |
| Q50200755 | Development of a pre-glycoengineered CHO-K1 host cell line for the expression of antibodies with enhanced Fc mediated effector function. |
| Q39545373 | Effects of cell culture conditions on antibody N-linked glycosylation--what affects high mannose 5 glycoform |
| Q27678524 | Engineering Hydrophobic Protein–Carbohydrate Interactions to Fine-Tune Monoclonal Antibodies |
| Q38752663 | Enhanced Effector Functions Due to Antibody Defucosylation Depend on the Effector Cell Fcγ Receptor Profile. |
| Q39484103 | Fucose content of monoclonal antibodies can be controlled by culture medium osmolality for high antibody-dependent cellular cytotoxicity |
| Q35591653 | Fucosyltransferase 1 mediates angiogenesis in rheumatoid arthritis |
| Q39559611 | Glycoengineered Pichia produced anti-HER2 is comparable to trastuzumab in preclinical study. |
| Q28069362 | Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies |
| Q38994739 | Immunoglobulin Glycosylation Effects in Allergy and Immunity |
| Q37403194 | Improving effector functions of antibodies for cancer treatment: Enhancing ADCC and CDC |
| Q50237001 | Microheterogeneity of Recombinant Antibodies: Analytics and Functional Impact |
| Q33900595 | New paradigms for functional HIV-specific nonneutralizing antibodies |
| Q46089932 | Novel therapeutic targets along the Th17 pathway |
| Q44970905 | Online enzymatic sequencing of glycans from Trastuzumab by phospholipid-assisted capillary electrophoresis. |
| Q26787279 | Paradigms lost-an emerging role for over-expression of tight junction adhesion proteins in cancer pathogenesis |
| Q39662620 | Plant-Produced Trastuzumab Inhibits the Growth of HER2 Positive Cancer Cells |
| Q38408253 | Production, Characterization, and Biological Evaluation of Well-Defined IgG1 Fc Glycoforms as a Model System for Biosimilarity Analysis |
| Q38957490 | Regulation of antibody effector functions through IgG Fc N-glycosylation |
| Q92538845 | Selective Engagement of FcγRIV by a M2e-Specific Single Domain Antibody Construct Protects Against Influenza A Virus Infection |
| Q37599672 | Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms |
| Q35172546 | The emerging importance of α-L-fucose in human breast cancer: a review. |
| Q50115805 | The process defines the product: what really matters in biosimilar design and production? |
| Q37995919 | The role of sialic acid as a modulator of the anti-inflammatory activity of IgG. |
| Q37962332 | Treatment of HER2-positive breast cancer: current status and future perspectives. |
Search more.